AsedaSciences, Clyde Biosciences sign agreement to integrate cardiotoxicity screen
Apr 22, 2026
AsedaSciences signed a commercial agreement with Clyde Biosciences to integrate the CellOPTIQ cardiotoxicity screen into its 3RnD platform. The deal adds a validated in vitro CiPA assay for chemical and drug safety assessment.